Protein function is intimately connected with supramolecular chemistry: Substrate processing and various levels of regulation involve specific noncovalent interactions. Likewise, protein folding, assembly and protein-protein interactions are governed by intermolecular forces and their specific inhibition or support represents a very promising area for external interference, with profound mechanistic and therapeutic implications.
The CRC aims at applying recent knowledge and methods from supramolecular chemistry to achieve specific interaction with proteins by artificial ligands.
Frank-Gerrit Klärner and Thomas Schrader have designed and optimized molecular tweezers with a unique structure which makes them selective for lysine and arginine residues. Their fruitful collaboration with Gal Bitan from the David Geffen School of Medicine at the University of California, Los Angeles, revealed the ability of these tweezers to inhibit aberrant peptide and protein aggregation, which is a common pathogenic feature of neurodegenerative diseases like Alzheimer’s, Parkinson’s or Transthyretin (TTR)-related Amyloidosis. Latest promising results offer the prospect of developing molecular tweezers as suitable drug candidates. Thomas Schrader, Frank-Gerrit Klärner and Gal Bitan, who was also an invited guest professor of our CRC, have now summarized the properties and the potential of these molecular tweezers in the renowned journal Chemical Communications: “Molecular tweezers for lysine and arginine – powerful inhibitors of pathologic protein aggregation”. This Feature Article carries the issue’s front cover.
Our second Graduate Student Symposium took place from 31st of August to 2nd of Septemberat the GHotel in Hannover. 45 graduate students from the CRC1093 of Duisburg-Essen and the CRC765 of Berlin discussed latest results within the field of supramolecular chemistry. Read More
"PLUS3" Grant from the Boehringer Ingelheim Foundation
CRC1093 Principal Investigator Dr. Elsa Sánchez-García received the prestigious “PLUS3” grant from the Boehringer Ingelheim Foundation. This programme supports her project focusing on the computational design of molecules with therapeutic potential. Read more
Drug Discovery and its Challenges
The drug discovery workshop provides insight into applied research in the pharmaceutical industry from target identification to clinical studies and emphasises the challenges of classical and modern screening methods. The workshop is a full day seminar with some short introductory lectures given by Oliver von Ahsen and literature talks that should be prepared and presented by the students in teams of two.
Lecturer: Oliver von Ahsen (Global Drug Discovery - Bayer Pharma AG, Berlin)